Abstract

In this present study a new co-crystals of zoledronic acid with DL-tartaric acid and nicotinamide has been developed with improved solubility. Zoledronic acid is a class III drug with poor oral bioavailability due to its poor permeability and low aqueous solubility; hence an attempt has been made to improve its solubility by co-crystallization technology. Pharmaceutical cocrystals are multi-component crystals with a stoichiometric ratio of active pharmaceutical ingredients (APIs) and cocrystal coformers (CCFs) that are assembled by noncovalent interactions such as hydrogen bonds, π-π packing, and Vander Waals forces. In this study the coformers selected were DL-tartaric acid and nicotinamide based on ease of hydrogen bond formation. The co-crystal of zoledronic acid with DL-tartaric acid were prepared in three ratios (1 : 1, 1 : 2 and 2 : 1) by slow solvent evaporation method and with nicotinamide in 1 : 1 ratio by dry grinding method. The formation of co-crystal was confirmed by powder X-ray diffractometry (PXRD), differential scanning calorimetry (DSC) and Fourier transform (FT)IR. The dynamic solubility of co-crystals with DL-tartaric acid in the ratios 1 : 1, 1 : 2 and 2 : 1 increased by fold as compared to pure drug.

Original languageEnglish
Pages (from-to)816-823
Number of pages8
JournalChemical and Pharmaceutical Bulletin
Volume67
Issue number8
DOIs
Publication statusPublished - 01-01-2019

Fingerprint

zoledronic acid
Solubility
Niacinamide
Crystals
Pharmaceutical Preparations
Hydrogen
Hydrogen bonds
Differential Scanning Calorimetry
Fourier Analysis
Crystallization
Powders
Biological Availability
Permeability
X ray diffraction analysis
X-Rays
Differential scanning calorimetry
Technology
Fourier transforms
Evaporation
tartaric acid

All Science Journal Classification (ASJC) codes

  • Chemistry(all)
  • Drug Discovery

Cite this

@article{90f6c2dbfe954141a9966a8e9257c643,
title = "Designing of stable co-crystals of zoledronic acid using suitable coformers",
abstract = "In this present study a new co-crystals of zoledronic acid with DL-tartaric acid and nicotinamide has been developed with improved solubility. Zoledronic acid is a class III drug with poor oral bioavailability due to its poor permeability and low aqueous solubility; hence an attempt has been made to improve its solubility by co-crystallization technology. Pharmaceutical cocrystals are multi-component crystals with a stoichiometric ratio of active pharmaceutical ingredients (APIs) and cocrystal coformers (CCFs) that are assembled by noncovalent interactions such as hydrogen bonds, π-π packing, and Vander Waals forces. In this study the coformers selected were DL-tartaric acid and nicotinamide based on ease of hydrogen bond formation. The co-crystal of zoledronic acid with DL-tartaric acid were prepared in three ratios (1 : 1, 1 : 2 and 2 : 1) by slow solvent evaporation method and with nicotinamide in 1 : 1 ratio by dry grinding method. The formation of co-crystal was confirmed by powder X-ray diffractometry (PXRD), differential scanning calorimetry (DSC) and Fourier transform (FT)IR. The dynamic solubility of co-crystals with DL-tartaric acid in the ratios 1 : 1, 1 : 2 and 2 : 1 increased by fold as compared to pure drug.",
author = "Abhishek Varma and Prasanna Laxmi and Aravind Pai and Girish Pai and Vasantharaju, {S. G.} and Sathyanarayana, {Muddukrishna Badamane}",
year = "2019",
month = "1",
day = "1",
doi = "10.1248/cpb.c19-00202",
language = "English",
volume = "67",
pages = "816--823",
journal = "Chemical and Pharmaceutical Bulletin",
issn = "0009-2363",
publisher = "Pharmaceutical Society of Japan",
number = "8",

}

Designing of stable co-crystals of zoledronic acid using suitable coformers. / Varma, Abhishek; Laxmi, Prasanna; Pai, Aravind; Pai, Girish; Vasantharaju, S. G.; Sathyanarayana, Muddukrishna Badamane.

In: Chemical and Pharmaceutical Bulletin, Vol. 67, No. 8, 01.01.2019, p. 816-823.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Designing of stable co-crystals of zoledronic acid using suitable coformers

AU - Varma, Abhishek

AU - Laxmi, Prasanna

AU - Pai, Aravind

AU - Pai, Girish

AU - Vasantharaju, S. G.

AU - Sathyanarayana, Muddukrishna Badamane

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In this present study a new co-crystals of zoledronic acid with DL-tartaric acid and nicotinamide has been developed with improved solubility. Zoledronic acid is a class III drug with poor oral bioavailability due to its poor permeability and low aqueous solubility; hence an attempt has been made to improve its solubility by co-crystallization technology. Pharmaceutical cocrystals are multi-component crystals with a stoichiometric ratio of active pharmaceutical ingredients (APIs) and cocrystal coformers (CCFs) that are assembled by noncovalent interactions such as hydrogen bonds, π-π packing, and Vander Waals forces. In this study the coformers selected were DL-tartaric acid and nicotinamide based on ease of hydrogen bond formation. The co-crystal of zoledronic acid with DL-tartaric acid were prepared in three ratios (1 : 1, 1 : 2 and 2 : 1) by slow solvent evaporation method and with nicotinamide in 1 : 1 ratio by dry grinding method. The formation of co-crystal was confirmed by powder X-ray diffractometry (PXRD), differential scanning calorimetry (DSC) and Fourier transform (FT)IR. The dynamic solubility of co-crystals with DL-tartaric acid in the ratios 1 : 1, 1 : 2 and 2 : 1 increased by fold as compared to pure drug.

AB - In this present study a new co-crystals of zoledronic acid with DL-tartaric acid and nicotinamide has been developed with improved solubility. Zoledronic acid is a class III drug with poor oral bioavailability due to its poor permeability and low aqueous solubility; hence an attempt has been made to improve its solubility by co-crystallization technology. Pharmaceutical cocrystals are multi-component crystals with a stoichiometric ratio of active pharmaceutical ingredients (APIs) and cocrystal coformers (CCFs) that are assembled by noncovalent interactions such as hydrogen bonds, π-π packing, and Vander Waals forces. In this study the coformers selected were DL-tartaric acid and nicotinamide based on ease of hydrogen bond formation. The co-crystal of zoledronic acid with DL-tartaric acid were prepared in three ratios (1 : 1, 1 : 2 and 2 : 1) by slow solvent evaporation method and with nicotinamide in 1 : 1 ratio by dry grinding method. The formation of co-crystal was confirmed by powder X-ray diffractometry (PXRD), differential scanning calorimetry (DSC) and Fourier transform (FT)IR. The dynamic solubility of co-crystals with DL-tartaric acid in the ratios 1 : 1, 1 : 2 and 2 : 1 increased by fold as compared to pure drug.

UR - http://www.scopus.com/inward/record.url?scp=85070618880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070618880&partnerID=8YFLogxK

U2 - 10.1248/cpb.c19-00202

DO - 10.1248/cpb.c19-00202

M3 - Article

VL - 67

SP - 816

EP - 823

JO - Chemical and Pharmaceutical Bulletin

JF - Chemical and Pharmaceutical Bulletin

SN - 0009-2363

IS - 8

ER -